drugset / Trial / NCT00051662

Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis

NCT00051662

Phase 1 Completed 45 enrolled XOMA (US) LLC
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of psoriatic arthritis (PsA)

Timeline

Start
Primary completion
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject efalizumab Monoclonal antibody

Indications